1 Reynaud’s and Scleroderma Association. Coping with Raynaud’s. www.raynauds.org.uk/raynauds/coping-with-raynauds.
2 Fraenkel L. Raynaud’s phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 2002;4:123-8.
3 Palmer K, Griffin M, Syddall H, Pannett B, Cooper C, Coggon D. Prevalence of Raynaud’s phenomenon in Great Britain and its relation to hand transmitted vibration: a national postal survey. Occup Environ Med 2000;57:448-52.
4 Reynaud’s and Scleroderma Association. Digital ulcers. www.raynauds.org.uk/component/content/article/138.
5 Riera G, Vilardell M, Vaqué J, Fonollosa V, Bermejo B. Prevalence of Raynaud’s phenomenon in a healthy Spanish population. J Rheumatol 1993;20:66-9.
6 Koening M, Joyal F, Fritzler M, Roussin A, Abrahamowicz M, Boire C, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
7 Wigley F. Raynaud’s phenomenon. N Engl J Med 2002;347:1001-8.
8 Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 2005;44:587-96.
9 Health and Safety Executive. Control of vibration at work regulations 2005. www.hse.gov.uk/vibration/hav/regulations.htm.
10 Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 2010;62:2595-604.
11 Avouac J, Mogavero G, Guerini H, Drapé J, Mathieu A, Kahan A, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 2011;70:630-3.
12 Bakst R, Merola JE, Franks AG Jr, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol 2008;59:633-53.
13 Malefant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) 2009;48:791-5.
14 Suter LG, Murabito JM, Felson DT, Fraenkel L. Smoking, alcohol consumption, and Raynaud’s phenomenon in middle age. Am J Med 2007;120:264-71.
15 Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial. Vasc Med 2002;7:265-7.
16 Choi WS, Choi CJ, Kim KS, Lee JH, Song CH, Chung JH, et al. To compare the efficacy and safety of nifedipine sustained release with Ginkgo biloba extract to treat patients with primary Raynaud’s phenomenon in South Korea; Korean Raynaud study (KOARA study). Clin Rheumatol 2009;28:553-9.
17 Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford) 2005;44:145-50.
18 Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in  primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002;41:324-8.
19 Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum 2009;60:870-7.
20 Belch J, Fiorentino D, Denton C, Herrick A, Sule S, Steen V, et al. MQX-03, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud’s phenomenon [abstract]. Arthritis Rheum 2008;58(9 suppl):S622.
21 Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
22 Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;2:CD000953.
23 Kawald A, Burmester GR, Huscher D, Sunderkotter C, Riemerkasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol2008;35:1830-7.
24 Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, et al. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 2006;45:999-1004.
25 Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon: a randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.
26 Herrick AL. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
27 Schiopu E, Vivien M, Impens A, Rothman J, McCloskey D, Wilson J, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
28 Shenoy P, Kumar S, Lalan KJ, Choudhary C, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010;49:2420-8.
29 Rosato E Borghese F, Pisarri S, Salsano F. Long-term therapy with NAC, in patients with SSc, has a durable effectiveness on ischemic ulcers and Raynaud’s phenomenon. Clin Rheumatol 2009;28:1379-84.
30 Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001;28:2257-62.
31 Dziadzio M, Denton CP, Smith R, Howell A, Blann A, Bowers E, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma. Arthritis Rheum 1999;42:2646-55.
32 Gliddon A, Dore C, Black CM, McHugh N, Moots R, Denton CP, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon. Arthritis Rheum 2007;56:3837-46.
33 Wollershiem H, Thien T, Fennis J, Van Elteren P, Van’t Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther 1986;40:219-25.